Placenta Previa and Placenta Percreta Patients During the Third Trimester

NCT06849349 | Completed

• 1 other identifier: MCBU- Perkreata-previa
• Study Type: observational
• Target: 48
• Locations: 1 country
• Sites: 1

Brief Summary

Placenta previa can cause a risk of severe bleeding during labor. Placenta previa is usually classified into four different types: total, partial, marginal and asymptomatic. The condition is diagnosed by ultrasonography later in pregnancy and its management varies depending on the location of the placenta and the presence of bleeding. Studies show that the increased frequency of placenta previa is associated with increased cesarean section rates and maternal age (1). Furthermore, the effects of placenta previa on maternal and fetal morbidity can be reduced with proper management (2). Placenta percreata is a condition in which the placenta invades the myometrium (uterine muscle) and serosa (outer surface of the uterus). This can make postpartum detachment of the placenta difficult, leading to severe bleeding and complications. Placenta perforata is often associated with placenta previa and may require surgical intervention. Ultrasonography and magnetic resonance imaging (MRI) are used to diagnose this condition. Risk factors include previous cesarean deliveries and placenta previa (3). Placenta percreata requires careful management as it increases the risk of maternal mortality and morbidity (4). In this study, we aimed to investigate the levels of decorin, laminin, collagen-1, TGFβ-1, PDGF in placentas of pregnant women with placenta percreata and previa.

Conditions

Placenta Previa; Placenta Percreta, Third Trimester

Keywords

Placenta Percreata; Plaenta Previa; GLYCOPROTEIN; FIBER; GROWTH FACTORS

Outcome Measures

Primary Outcomes (4)

• Mean Immunohistochemical Staining Score of Decorin, Laminin, Collagen-I, TGFβ-1, and PDGF in Placenta Percreta Tissues

  Placental tissue samples obtained at delivery from patients with placenta percreta will undergo immunohistochemical staining for decorin, laminin, collagen-I, TGFβ-1, and PDGF. Staining intensity and distribution will be quantified using the H-score method.

  Baseline

• Maternal and Cord Blood Concentrations of TGFβ-1 and Decorin in Placenta Percreta Pregnancies

  Maternal and cord blood samples collected from pregnancies complicated by placenta percreta will be analyzed for TGFβ-1 and decorin concentrations using biochemical assay methods.

  Baseline

• Mean Immunohistochemical Staining Score of Decorin, Laminin, Collagen-I, TGFβ-1, and PDGF in Placenta Previa Tissues

  Placental tissue samples obtained at delivery from patients with placenta previa will undergo immunohistochemical staining for decorin, laminin, collagen-I, TGFβ-1, and PDGF. Staining intensity and distribution will be quantified using the H-score method.

  baseline

• Maternal and Cord Blood Concentrations of TGFβ-1 and Decorin in Placenta Previa Pregnancies

  Maternal and cord blood samples collected from pregnancies complicated by placenta previa will be analyzed for TGFβ-1 and decorin concentrations using biochemical assay methods.

  baseline

Study Arms (3)

Group 1: Pregnant women with Placenta Percreata

Group 2: Pregnant women with Placenta Previa

Group 3: Control

Eligibility Criteria

• Age: 18 Years - 50 Years
• Sex: female
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)
• Sampling Method: Probability Sample

Study Population

women of Placenta percreata woman of Placenta previa

You may qualify if:

• Healthy pregnancy under 37 weeks
• Age range 18-50
• Being literate in Turkish
• Not having any additional disease
• Agreeing to participate in the study

You may not qualify if:

• High-risk pregnancies (gestational hypertension, preeclampsia, HELLP syndrome, chronic hypertension, gestational and pregestational diabetes, cholestasis, intrauterine growth retardation, etc.)
• Multiple pregnancy
• Pregnant women under the age of 18
• Smoking
• Medication use (excluding routinely used food supplements during pregnancy)
• Additional disease (thyroid, renal failure, liver failure, hepatitis, heart disease, connective tissue disease, etc.)
• Immunosuppressive use
• Presence of active or chronic infection
• Presence of active or chronic inflammatory disease
• Patients who gave birth at an external center or later chose to withdraw from the study
• Premature birth of patients included in the control group

Sponsors & Collaborators

• Celal Bayar University: lead

Study Sites (1)

Manisa Celal Bayar University

Manisa, Turkey (Türkiye)

Location

Biospecimen

Retention: SAMPLES WITH DNA

placenta tissues

MeSH Terms

Conditions

Placenta Accreta; Placenta Previa

Condition Hierarchy (Ancestors)

Obstetric Labor Complications; Pregnancy Complications; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Placenta Diseases

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 11 Months
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 22, 2025
• First Posted: February 27, 2025
• Study Start: February 20, 2025
• Primary Completion: June 20, 2025
• Study Completion: November 20, 2025
• Last Updated: May 20, 2026

Record last verified: 2026-05

Data Sharing

• IPD Sharing: Will not share

Locations

TU (1)